Shots:

• The P-III POSEIDON trial evaluates Imfinzi (1500mg- q3w- FD- for 4 cycles) + Pt-based CT or Imfinzi + Tremelimumab + CT vs CT alone in 1013 patients with mNSCLC
• The results showed an improvement in OS & PFS- 28% reduction in risk of cancer progressing or death with an m-PFS (6.2 vs 4.8mos.)- 23% reduction in risk of death @16wks.- m-OS (14.0 vs 11.7mos.)- patients were alive @2yrs. (33% vs 22%). The safety profile was consistent with known profiles of therapies & no new safety signals were observed
• Imfinzi is further being evaluated across all stages of lung cancer and in other tumor types. The combination therapy also tested for lung cancer- bladder cancer- and liver cancer

  | Ref: AstraZeneca | Image: New Europe